| Q24548250 | 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways |
| Q40434680 | Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter |
| Q36936510 | Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish |
| Q38712212 | Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. |
| Q39128976 | Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses |
| Q47422245 | Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments |
| Q38763094 | Development of Selective Covalent Janus Kinase 3 Inhibitors. |
| Q40288223 | Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. |
| Q60923199 | Ex Vivo Transposon-Mediated Genetic Screens for Cancer Gene Discovery |
| Q35120026 | Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo |
| Q37316601 | Following the cytokine signaling pathway to leukemogenesis: a chronology |
| Q33611301 | Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53 |
| Q36740156 | In vivo identification of novel STAT5 target genes |
| Q27004027 | Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia |
| Q26782539 | JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications |
| Q33586552 | Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies |
| Q34071332 | Jaks and stats as therapeutic targets |
| Q26991810 | Janus kinase deregulation in leukemia and lymphoma |
| Q24322021 | Janus kinases in immune cell signaling |
| Q35879915 | Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics |
| Q41528529 | Modeling ETV6-JAK2-induced leukemia: insights from the zebrafish |
| Q42433996 | Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade |
| Q92814428 | Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers |
| Q27633822 | Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression |
| Q37291219 | Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies |
| Q38116768 | STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention |
| Q33559005 | Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation |
| Q34627064 | Stat proteins and oncogenesis |
| Q42657514 | Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. |
| Q35822851 | Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity |
| Q36836799 | TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia |
| Q37347522 | Targeting signal transducer and activator of transcription signaling pathway in leukemias. |
| Q33613105 | The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors |
| Q38349780 | The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines |
| Q24308570 | The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction |
| Q24658483 | Therapeutic targeting of Janus kinases |
| Q34182738 | Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase |
| Q37919976 | Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies |
| Q28081638 | Zebrafish as a model for leukemia and other hematopoietic disorders |
| Q34570939 | t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. |